Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Danish biotech company Genmab has regained all rights to the HuMax-CD4 antibody, which is used to treat T-cell lymphomas, from Merck Serono.
Subscribe to our email newsletter
Genmab is now planning to expand the antibody’s development in cancer, specifically the existing non-cutaneous T-cell lymphoma and cutaneous T-cell lymphoma clinical programs, and to create a unibody for the HIV virus, by targeting the CD4 receptor.
Worldwide rights to HuMax-CD4 were previously licensed to Merck Serono in August 2005.